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ABSTRACT 39 
The impact of cerebral Epo in the regulation of the hypercapnic ventilatory response (HcVR) is 40 
controversial. While we reported that cerebral Epo does not affect the central chemosensitivity in C57Bl6 41 
mice receiving an intracisternal injection of sEpoR (the endogenous antagonist of Epo), a recent study in 42 
transgenic mice with constitutive high levels of human Epo in brain and circulation (Tg6) and in brain only 43 
(Tg21), showed that Epo blunts the HcVR, maybe by interacting with central and peripheral 44 
chemoreceptors. High Epo serum levels in Tg6 mice lead to excessive erythrocytosis (hematocrit about 45 
80-90%), the main symptom of chronic mountain sickness (CMS). These latter results support the 46 
hypothesis that reduced central chemosensitivity accounts for the hypoventilation observed in CMS 47 
patients. To solve this intriguing divergence, we re-evaluate HcVR in Tg6 and Tg21 mouse lines, by 48 
assessing the metabolic rate ( = O2 consumption; and = CO2 production), a key factor 49 
modulating ventilation, which effect was not considered in the previous study. Our results showed that the 50 
decreased HcVR observed in Tg6 mice (~70% reduction; p<0.01) was due to a significant decrease in the 51 
metabolism (~40%; p<0.0001) rather than Epo’s effect on CO2 chemosensitivity. Additional analysis in 52 
Tg21 mice did not revealed differences of HcVR or metabolism. We concluded that cerebral Epo does not 53 
modulate the central chemosensitivity system, and that a metabolic effect upon CO2 inhalation is 54 
responsible for decreased HcVR observed in Tg6 animals. As CMS patients also show decreased HcVR, 55 
our findings might help to better understand respiratory disorders at high altitude. 56 
 57 
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INTRODUCTION 59 
Excessive erythrocytosis is a main symptom of chronic mountain sickness (CMS, or Monge´s disease), a 60 
clinical syndrome that affects people who reside at altitudes higher than 2,500 m above sea level. It is 61 
estimated that about 5–10% of the world’s population living at high-altitude may develop this illness (27, 62 
43). In the Andes of Bolivia and Peru (> 4,000m), CMS affects 15-20% of the adult male population, and 63 
its prevalence increases with age, rising up to 30% by the age of 50 (25, 31). Chronic hypoxemia and 64 
neurological symptoms (such as headache, fatigue, somnolence, and alterations of sleep and memory) 65 
(28, 36) are also associated to CMS. Moreover, excessive erythrocytosis leads to life-threatening 66 
cyanosis, hyperemia, increased blood viscosity, thrombosis, and pulmonary hypertension (45). 67 
Remarkably, despite hypoxemia, it has been suggested that the basal ventilation and the hypoxic 68 
ventilatory response of CMS patients compared to healthy dwellers at same altitudes are reduced (28, 69 
36). This observation led to the hypothesis that the ability of carotid bodies to sense the blood’s PaO2 in 70 
CMS patients is blunted (28, 36). Moreover, there are reports suggesting that the CO2 chemosensitivity in 71 
CMS patients is also decreased, as they show a blunted hypercapnic ventilatory response (HcVR) 72 
compared to non-affected highlanders (40). In line, as the work of Leon-Velarde et al, showed no 73 
differences in the hypoxic ventilatory response between healthy highlanders and CMS patients, it was 74 
suggested that chronic hypoxemia, excessive erythrocytosis and CMS should be associated to a 75 
diminished CO2 chemosensitivity, rather than a reduced hypoxic ventilatory response (26). It was also 76 
observed that in the course of the disease CMS patients develop a time-dependent increase of 77 
hemoglobin, accompanied by elevated PaCO2 and reduced of PaO2 (32). Moreover, hypoxia caused a 78 
greater increase in total CO2 sensitivity in sea level than in the high altitude and CMS subjects combined 79 
(11). Similar results were also reported previously by Fatemian et al., showing that total (but nor 80 
peripheral) chemosensitivity to CO2 in hypoxia was higher in subjects at sea level compared to high 81 
altitude CMS patients (12). Indeed, sensing PaCO2 provides a strong excitatory input to the respiratory 82 
rhythm generator through activation of chemoreceptors in the brainstem (33) and in the carotid bodies 83 
(13). Even a small increase in arterial PCO2 evokes a robust increase in the respiratory activity: in humans 84 
a 1mmHg increase in PaCO2 may lead to a 2L/min increase in lung ventilation (42). Consequently, it was 85 
also postulated that hypoventilation observed in CMS patients might be secondary to reduced sensitivity 86 
to CO2, and as such CO2 sensitivity as an important factor in the etiology of this disease.  87 
We previously reported that - apart from its role in erythropoiesis - Epo is a potent stimulator of the 88 
hypoxic ventilatory response by interacting with respiratory centers in the brainstem (1, 41). On the other 89 
hand, by blocking the Epo’s activity in the brainstem of adult C57Bl6 mice by intracisternal injections of the 90 
soluble Epo receptor (sEpoR), we reported that Epo reduced the basal minute ventilation by ~25%, but did 91 
not affect the central chemosensitivity (2). In contrast, a recent study using transgenic mice (Tg6: Epo 92 
overexpression in brain and circulation; Tg21: Epo overexpression in brain), suggested that Epo, 93 
presumably by interacting with central and peripheral respiratory chemocenters, blunts the HcVR (29). As 94 
such, the relevant question whether Epo decreases (or not) the CO2 chemosensitivity is debated. 95 
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Moreover, as Tg6 mice show excessive erythrocytosis (hematocrit about 80-90%), the Tg6 strain is an 96 
interesting animal model to investigate if Epo and/or excessive erythrocytosis leads to hypoventilation in 97 
CMS patients due to reduced sensitivity to CO2. Thus, in this work we re-evaluated the hypercapnic 98 
ventilation of Tg6 and Tg21 mice, and additionally assessed the metabolic rate ( = O2 consumption 99 
and = CO2 production), a key factor modulating ventilation, which effect was neglected in the 100 
previous study performed with these transgenic mice. Our working hypothesis was that when animals are 101 
exposed to hypercapnic conditions the decreased HcVR reported in Tg6 is due to changes in the 102 
metabolism, rather than due to Epo’s modulation of the neural chemosensitivity. Indeed, the literature 103 
reports that hypercapnia alters , and proposes that numerous factors may contribute to such 104 
metabolic alteration (23). In line with these observations our results suggest that cerebral Epo does not 105 
alter the central CO2 chemosensitivity and that the increased amount of circulating Epo, and the resulting 106 
excessive erythrocytosis may be crucial factors mediating a decreased metabolic response under CO2 107 
stimulation, which in turn will blunt the HcVR. 108 
109 
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MATERIAL & METHODS 110 
Animals 111 
Detailed description of Tg6 and Tg21 strains were reported previously (37, 47). In brief, both transgenic 112 
strains are bread in a C57BL/6 back ground. The Tg6 mouse line showed increased Epo levels in lungs 113 
(12-folds / WT) and brain (26-folds / WT), accompanied by a doubled hematocrit value (Fig 1) (19). Half of 114 
the offspring were hemizygous for the transgene, while the other half were WT and thus were used as 115 
control animals (WT-Tg6) (44). Similarly, Tg21 heterozygotes mice, overexpressing Epo in the brain (4-116 
folds/WT; Fig 1), were backcrossed with C57Bl/6 mice for more than six generations to obtain the 117 
corresponding control mice (WT-Tg21) used in this study. Here we used adult (2 - 3 months age) male 118 
Tg6 (hemizygous), Tg21 (homozygous) and corresponding controls. Animal experiments were approved 119 
by the Laval University Animal Ethics Committee (protocol #12-119-1) and carried out in accordance with 120 
the standards and guidance of the Canadian Council on Animal Care. 121 
 122 
Respiratory recordings using whole-body plethysmography 123 
Set-up details.  124 
We used whole body plethysmography to record respiratory frequency (fR), tidal volume ( ), and minute 125 
ventilation (  = fR x ). Minute ventilation is defined as the volume of inhaled or exhaled gas per 126 
minute. Basal minute ventilation is the minute ventilation under normocapnic/normoxic conditions, while 127 
ventilatory response to hypercapnia is the difference between the basal minute ventilation and the minute 128 
ventilation recorded under hypercapnic stimulation. Animals were place into a 600 ml plethysmograph 129 
chamber (Emka, Technologies, Paris, France) continuously supplied with fresh air (around 180 ml.min-1) 130 
at room temperature. A differential pressure transducer (Emka technologies) was connected between the 131 
recording chamber and the built-in reference chamber. A single injection of 500 µl of air inside the 132 
chamber was used for calibration of the flow trace. A subsampling pump was used to draw (~50-75 133 
ml/min) a sample of outflowing air for analysis of respiratory gases. In the outflowing line water pressure 134 
and CO2 levels were measured with dedicated gas analysers (respectively RH 300 - Sable Systems 135 
International, Las Vegas, NV, USA - and CD-3A - AEI technologies, Pittsburgh, PA, USA). Oxygen levels 136 
in the inflowing and outflowing gas lines were measured with a dual channel O2 analyzer (S3-A/II - AEI 137 
Technologies). All signals were acquired and recorded on a computer using the Spike 2 software 138 
(Cambridge Electronic Design, Cambridge, UK), and used offline to calculate respiratory frequency (fR), 139 
tidal volume ( ), minute ventilation ( = fR x VT), CO2 production ( ), and O2 consumption rate (140 
). Body weight was measured routinely after every experiment to express the tidal volume in ml/100g. 141 
Body temperature was measured at the beginning and at the end of the experiment with a rectal 142 
thermocouple probe (Physitemp). 143 
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 144 
Recordings and signal analysis 145 
After the animal familiarized within the plethysmography chamber (about 2 hours), basal ventilation was 146 
recorded at normocapnia (air) for 10 to 20 minutes. Hypercapnia was achieved by using a gas mixture 147 
containing 21% O2 , 5% CO2, in N2, and the recording lasted 10 min.  148 
During baseline recordings, the subsampling pump was connected to the inflowing gas line for 2 to 3 149 
minutes. This procedure was used to verify that the two channels of the O2 analyzer read similar values in 150 
the inflowing and outflowing gas lines, and to record the values of inflowing CO2 and H2O required for the 151 
calculation of metabolic rate (see below).  152 
Respiratory frequency and inspiratory volume were calculated breath-by-breath using a custom script in 153 
Spike 2, then values of baseline ventilation were determined on the portions of the recording during which 154 
the breathing pattern was stable and regular, with the lowest respiratory frequency. During hypercapnia 155 
we selected fragments of stable and regular breathing patterns. For metabolic rate, we used the portions 156 
of the recordings where CO2 in the outflowing gas line displayed the lowest value.  157 
The section of the calibrated flow trace corresponding to inspiration was integrated by the software, and 158 
the corresponding volume was corrected by using the standard equation described for whole body 159 
plethysmography (4). Tidal volume (VT), respiratory frequency (fR), minute ventilation ( ), oxygen 160 
consumption ( ) and CO2 production ( ) were calculated as previously described (1) by using 161 
standard equations.  162 
 163 
Quantification of hematocrit and Epo 164 
At the end of experimentation mice were anaesthetized by an intra-peritoneal injection of a mixture of 165 
ketamine (80 mg kg−1) and xylazine (10 mg kg−1). Blood samples were drawn by cardiac puncture into 166 
heparinized Ependorff tubes (for plasma collection after samples centrifugation at 18 000 g, 15 min; 167 
Heraeus Instruments Biofuge 15, USA) and from Ependorff tubes into capillary tubes, to assess the 168 
hematocrit percentage (after samples centrifugation at 20 000 RCF, 10 min; American scientific products, 169 
Haemofuge 1216, USA). In following, brain samples were obtained after transcardial perfusion of mice 170 
with phosphate buffer (0.1 m, pH7.4) and immediately frozen in liquid nitrogen. Total brain and plasma 171 
Epo concentration was determined using 125I-Epo-based radioimmunoassay (RIA-DiaSorin, Stillwater, MN, 172 
USA), accordingly to previous published protocols (Wenger et al., 1998; Soliz, et al., 2005). The lower 173 
detection limit for RIA was 4 U/l, the intra-assay/interasay variances was < 2% and <6%, respectively. All 174 
Epo determinations were performed in duplicate.  175 
 176 
Statistical analysis  177 
The differences between groups were evaluated with a two-way ANOVA for repeated measurement using 178 
groups as the independent variable and hypercapnia as the repeated variable. If the ANOVA gave 179 
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significant effects for groups, hypercapnia, or significant groups by hypercapnia interaction, we used a 180 
Fisher's LSD post-hoc analysis to test the effects of groups at each level of hypercapnia, or the effects of 181 
hypercapnia within each group. All analysis and graphs were done with the GraphPad prism 6.0 software 182 
(La Jolla, CA, USA). The reported values are means ± SEM. Differences were considered significant at 183 
two-tailed: *p <0.05 and ***p<0.0001. 184 
 185 
RESULTS 186 
Tg6 mice show a marked reduction of the hypercapnic ventilatory response (HCVR) 187 
As expected, compared to WT-Tg6 control animals, Tg6 mice showed increased levels of hematocrit and 188 
Epo in plasma and brain (Fig 1 and table 1). Ventilatory ( , fR and VT) and metabolic ( , ) 189 
parameters were evaluated in transgenic Tg6 and WT-Tg6 control mice under basal normocapnic 190 
conditions. Neither ventilatory ( , fR and VT) nor metabolic ( , ) parameters were found to be 191 
different between strains under a normocapnic environment (Table 1 and Fig 2A-E). However, once 192 
exposed to hypercapnia, Tg6 showed a 70% reduction in ventilatory response (Fig 2A) as compared to 193 
control mice. This decreased ventilatory response was due to a significant reduction of the VT (Fig 2C) 194 
and no changes in fR (Fig 2B). Moreover, the evaluation of metabolism under hypercapnia showed a 195 
significant decreased  and  in transgenic mice in comparison to control WT-Tg6 (Fig 2D,E). As 196 
result, the respiratory equivalent ratio for O2 ( / ) or CO2 ( / ) was similar in control and Tg6 197 
mice (Table 1). These data demonstrate that the blunted ventilation observed in Tg6 mice under 198 
hypercapnia, is due to a significant reduction of the metabolism rather than the impact of Epo in the neural 199 
chemoregulation to CO2 (Fig 2 F-G). 200 
 201 
Tg21 mice, overexpressing Epo in brain only, do not show altered hypercapnic ventilatory 202 
response  203 
As our previous experiments do not allow differentiating between the impact of Epo in central or peripheral 204 
centers controlling ventilation, in a next step we used our phethysmography system to evaluated the 205 
hypercapnic ventilatory response in Tg21 transgenic mice (and corresponding control mice) 206 
overexpressing Epo only in the brain only (Fig 1C). Our results showed that under normocapnic and 207 
hypercapnic conditions both the ventilatory ( , VT, fR), and metabolic (  and ) parameters were 208 
similar between transgenic and control animals (Table 2 and Fig 3A-E). Accordingly, /  and /209 
are similar between strains (Fig 3F,G). These results are in line with our previous report in which the 210 
intracisternal injections of the endogenous Epo antagonist (the soluble Epo receptor, sEpoR), despite 211 
decreasing basal ventilation, did not affected the central chemosensitivity (2). All together, our present and 212 
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previous results strongly suggest that cerebral Epo does not affect the central chemosensitivity.213 
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DISCUSSION 214 
In the present study we investigated the HcVR of a transgenic mouse line (Tg6) that shows high levels of 215 
Epo in brain and plasma, and an excessive erythrocytosis similar to the observed in altitude dwellers 216 
suffering from chronic mountain sickness (CMS). Interestingly, as occurring in CMS patients, Tg6 mice 217 
significantly decrease their HcVR. Additional measurements of HcVR performed in a second line of 218 
transgenic mice overexpressing Epo in the brain only (Tg21), confirmed that cerebral Epo does not 219 
account for the neural modulation of central CO2 chemosensitivity. On the contrary, our results showed 220 
that a reduced metabolism (O2 consumption and CO2 production) is responsible of the decreased 221 
hypercapnic ventilation obtained in Tg6 mice. We concluded that circulating Epo overexpression and 222 
excessive erythrocytosis might be crucial factors enhancing the magnitude of the metabolic depression 223 
induced by CO2 inhalation. 224 
 225 
Previous studies performed on mice in our laboratory have shown that Epo and its receptor are widely 226 
distributed in the brainstem respiratory groups (41). Moreover we reported that cerebral Epo activates the 227 
hypoxic ventilatory response by interacting with the respiratory centers in the brainstem. In vitro 228 
experiments performed in brainstem-spinal cord preparations (en bloc technique) supported these results 229 
by showing that Epo is indeed a key regulator of oxygen homeostasis of the central respiratory network 230 
during both normoxia and hypoxia (1, 8-10, 24). On the other hand, as the brainstem is the main structure 231 
containing the CO2 chemosensors (17, 18, 34), it was also hypothesized that cerebral Epo might in 232 
addition modulate the ventilatory response to hypercapnia. However, so far, the results obtained in our 233 
and other laboratories have shown contradictory results. By performing an intracisternal injection (cisterna 234 
Magna) of the endogenous antagonist of Epo (the sEpoR), we showed that cerebral Epo does not affect 235 
the central CO2 chemosensitivity of C57BL6 mice (2). However, a recent study in which Tg6 and Tg21 236 
mice were used, suggests that Epo decreases the HcVR, maybe by interacting with the central and 237 
peripheral chemoreceptors (29). To solve this divergence, here we re-evaluate the HcVR in Tg6 and Tg21 238 
animal strains by additionally measuring the metabolism (  and ). Indeed, the literature reveals 239 
contradictory effects of hypercapnia on . Increase  and ventilation was observed in ponies, the 240 
former being attributed to the energetic cost of hyperventilation (23), no effect on  was reported in rats 241 
exposed to 2 and 5% CO2 (3, 39), and decreased  was described in cats exposed to 4% CO2 (38). 242 
Finally, although the mechanisms involved are not well understood, it is know that hypercapnia elicits 243 
hypothermia in a number of vertebrates (3). As such, although this response seems to be widespread 244 
among mammals, still little is known about the impact of metabolic regulation on the hypercapnic 245 
stimulation of ventilation (7). We reasoned that, showing considerable physiological changes associated 246 
with the regular oxygen usage and energy production (such as doubled hematocrit, doubled hemoglobin 247 
concentration, high blood viscosity, tripled amount of systemic NO, massive increase of plasma and 248 
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cerebral Epo), Tg6 mice appear to adjust their metabolism to cope with extreme respiratory challenges 249 
such hypercapnia. Accordingly to this hypothesis our results showed that Tg6 mice elicited a 70% 250 
reduction of the HcVR, in association with a severe reduction of the metabolism (  and ). As the 251 
ventilatory differences between transgenic Tg6 and control animals disappeared when the ventilatory 252 
equivalent ratio for O2 ( / ) and CO2 ( / ) were obtained, these results clearly suggest that 253 
the drastic HcVR depression of Tg6 mice was mediated by decreased metabolism. Furthermore, as these 254 
results are not conclusive in regard of the impact of central (and/or peripheral) Epo in the response to 255 
hypercapnia, we used a second transgenic mouse line, overexpressing Epo in the brain only (Tg21). Tg21 256 
mice compared to corresponding control animals showed similar HcVR, metabolism, and ventilatory 257 
equivalent ratio to O2 and CO2 ( /  and / ). Contrary to these results, the previous study in 258 
which HcVR was evaluated in transgenic mice, reported a decreased HcVR in Tg21 mice (29). However 259 
the published data show large variability and a p-value in the limit to allow the data to be considered as 260 
significantly different (p=0.043). On the contrary, our data shows small variability and a p-value far to the 261 
limit of significance (p=0.4754). In addition, more compelling is the fact that our current results are in line 262 
with our previous reported data in which central chemosensitivity was unaffected in C57Bl6 mice intra-263 
cisternaly treated with sEpoR (2). Of note, in current and previous (2) study animals were of 2-3 months of 264 
age, which certainly accounts for reducing the data variability. All together, our results support the notion 265 
that cerebral Epo is not implicated in the modulation of the central CO2 chemosensitivity, and that the 266 
decreased HcVR of Tg6 mice is mediated by a reduction in the metabolic drive, as can clearly be 267 
observed in the figure 1F&G. 268 
 269 
Regarding mechanisms, it seems important to recall that Tg6 animals show an increased constitutive 270 
expression of eNOS associated with a three-fold increased level of nitric oxide (NO) (37). Such NO 271 
augmentation prevents Tg6 mice from developing hypertension, stroke, myocardial infarction, or 272 
thrombolembolism. Moreover, when L-NAME (a inhibitor of NOS) was administrated by the drinking water, 273 
all treated Tg6 mice died after 52h (37). Apart however from its effects on vascular relaxation and 274 
antithrombotic functions (14, 20, 35), NO is an inhibitory messenger in the carotid body activity (46). 275 
Moreover, there are several pieces of evidence showing that NO is implicated in the regulation of the body 276 
temperature (3, 21). It was observed that the inhibition of NO in horses reduced by ~70% their sweat 277 
during exercise (22, 30), and NO is involved in the central mechanism of thermoregulation during fever in 278 
rabbits (16). Interestingly, the level of circulating NO is also increased (by 25-50%) at high altitude in 279 
Tibetans and Aymaras (from Bolivia) compared to the low altitude reference (5). As such, the 280 
augmentation of NO seems to be dependent on the need of vascular relaxation (as occurring in the 281 
erythrocythosis-mediated increase of blood density), and on the level of circulating Epo, as it has been 282 
reported that Epo induces NO production in microvascular endothelial cells of lungs (6, 15). Taken all this 283 
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evidences together, it is appealing to postulate that excessive erythrocytosis and overexpression of 284 
circulating Epo leads to NO overproduction reported in Tg6 mice. In turn, NO by modulating the carotid 285 
body activity, and by reducing the metabolism might contribute to the decreased ventilatory response of 286 
Tg6 mice exposed to CO2.  287 
 288 
Perspectives and significance 289 
Due to excessive erythrocytosis, Tg6 animals mimic some conditions of altitude dwellers suffering from 290 
CMS. However, as Tg6 mice also overexpress Epo in the brain, and neural Epo is a powerful ventilatory 291 
stimulant under normoxic and hypoxic condition (2, 41), these animals do not show baseline 292 
hypoventilation. Moreover, our previous work showed that the hypoxic ventilatory response of Tg6 animals 293 
was similar to control mice, and that the ventilatory response to hypoxic in transgenic mice was due to a 294 
remarkable increase of the respiratory frequency (most probably mediated by the overexpression of neural 295 
Epo), compensated by a significant decrease of VT. However, as our results suggest that neural Epo does 296 
not impact the central chemosensitivity, the Tg6 strain is a good model to study the HcVR of CMS 297 
patients. As such, it is tempting to speculate that the increased level of Epo availability (due to the reduced 298 
amount of plasmatic sEpoR (43)), and the excessive erythrocytosis occurring in CMS patients, may lead 299 
to an exaggerated production of circulating NO. Such NO imbalance, apart from inducing a vascular 300 
relaxation, may also contribute to hypoventilation and reduced ventilatory response to hypoxia and 301 
hypercapnia, by its action on the metabolism and in the inhibition of the carotid body activity. The 302 
relevance of our results is that - for the first time – convincing evidence is provided that decreased 303 
metabolism is responsible for the reduced ventilatory response to increased PaCO2 of CMS subjects. 304 
Further investigation in humans subjects are required to test this hypothesis, and also to determine if NO 305 
is the associated mechanism implicated. 306 
 307 
In summary our results show that the decreased HcVR of Tg6 mice is mediated by a significant reduction 308 
of the hypercapnic metabolism. Moreover, our data are in line with our previous report showing that neural 309 
Epo does not impact the central chemosensitivity. Finally, our results suggest that plasma Epo and 310 
excessive erythrocytosis could be major players in the observed reduction of the hypercapnic metabolism, 311 
possibly by producing an exaggerated production of circulating NO.  312 
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Figure legends 319 
 320 
Table 1. Comparison of ventilatory and metabolic parameters between control and Tg6 mice under 321 
baseline normocapnic and hypercapnic conditions. Animals per group: Tg6 = 9; Ctrl = 7. 322 
 323 
Table 2. Comparison of ventilatory and metabolic parameters between control and Tg21 mice under 324 
baseline normocapnic and hypercapnic conditions. Animals per group: Tg6 = 7; Ctrl = 6. 325 
 326 
Figure 1. Basal parameters in transgenic and contraol mice. Hematocrit (A) and Epo concentrations in 327 
plasma (pg/ml) (B) and brain (mU Epo/mg protein) (C) of transgenic (Tg6 and Tg21) mice and 328 
corresponding control animals. *p<0.01, Tg21 vs. Ctrl; ***p<0.0001 Tg6 vs. Ctrl. Animals per group: Tg6 = 329 
10; WT-Tg6 = 7 & Tg21 = 11; WT-Tg21 = 8. 330 
 331 
 332 
Fig 2. Hypercapnic ventilatory response in Tg6 mice is drastically reduced. A) Minute-ventilation (333 
), B) respiratory frequency (fR), C) tidal volume (VT), D) O2 consumption ( ), E) CO2 production (334 
), F) minute ventilation in response to O2 metabolism (  vs ), and G) the respiratory equivalent 335 
ratio for O2 ( / ) or CO2 ( / ) were recorded in male Tg6 and control (WT-Tg6) mice under 336 
normocapnic basal conditions and hypercapnia of 5%CO2. Dashed lines represents the values of VE/  337 
(panel F) or VE/  (panel G) reported for mice each normocapnic and hypercapnic levels respectively 338 
from bottom to top. All values are mean ± sem; ***p<0.0001, Tg6 vs. Ctrl at hypercapnia; animals per 339 
group = 9 – 7. 340 
 341 
Fig 3. Hypercapnic ventilatory response is not affected in Tg21 mice. A) Minute-ventilation ( ), B) 342 
respiratory frequency (fR), C) tidal volume (VT), D) O2 consumption ( ), E) CO2 production ( ), F) 343 
minute ventilation in response to O2 metabolism (  vs ), and G) the respiratory equivalent ratio for 344 
O2 ( / ) or CO2 ( / ) was similar in control and Tg6 mice were recorded in male Tg21 and 345 
control (WT-Tg21) mice under normocapnic basal conditions and hypercapnia of 5%CO2. Dashed lines 346 
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represents the values of VE/  (panel F) or VE/  (panel G) reported for mice each normocapnic and 347 
hypercapnic levels respectively from bottom to top. All values are mean ± sem; animals per group = 7 – 6.348 
VO2 VCO2
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Tg6 mice 
Parameter Group Condition Effect 
normocapnia 
mean ± SEM 
hypercapnia 
mean ± SEM 
Group Condition Interaction 
Minute 
ventilation 
WT-Tg6 148.0±21.4 434.8±58.8  
F=7.8 
p=0.011 
 
F=39.6 
p=0.0001 
 
F=7.8 
p=0.01 
Tg6 164.0±42.4 254.5±28.5 
Respiratory 
frequency         
WT-Tg6 226.2±32.6 321.6±21.5  
F=3.07 
p=0.092 
 
F=19.1 
p=0.0002 
 
F=1.002 
p=0.3 Tg6 218.2±29.5 263.0±14.5 
Tidal volume WT-Tg6 0.7±0.1 1.3±0.1  
F=7.7 
p=0.01 
 
F=46.3 
p=0.0001 
 
F=8.9 
p=0.006 Tg6 0.7±0.1 0.9±1.0 
O2 
consumption 
WT-Tg6 4.2±0.14 3.8±0.2  
F=18.9 
p=0.0009 
 
F=39.1 
p=0.0001 
 
F=13.8 
p=0.003 Tg6 4.1±0.1 2.7±0.1 
CO2 
production 
WT-Tg6 2.5±0.1 2.5±0.1  
F=24.5 
p=0.0003 
 
F=48.6 
p=0.0001 
 
F=59.2 
p=0.0001 Tg6 2.7±0.1 1.4±0.1 
VE/VO2 WT-Tg6 34.9±4.3 104.2±15.8  
F=0. 
p=0.4 
 
F=47.6 
p=0.0001 
 
F=2.0 
p=0.2 Tg6 39.2±9.2 97.5±15.3 
VE/VCO2 WT-Tg6 0.6±0.01 155.6±20.2  
F=0.5 
p=0.5 
 
F=34.6 
p=0.0001 
 
F=0.5 
p=0.5 Tg6 0.7±0.01 183.2±27.8 
hematocrit WT-Tg6 44.9±1.0  
P=0.8 
Tg6 78.4±1.4 
plasma Epo WT-Tg6 33.7±4.9   
p=0.4 
Tg6 415.4±9.3 
brain Epo WT-Tg6 11.6±2.1  
p=0.1 
Tg6 182.6±8.4 
Table 1 
. . 
. . 
Tg21 mice 
Parameter Group Condition Effect 
normocapnia 
mean ± SEM 
hypercapnia 
mean ± SEM 
Group Condition Interaction 
Minute 
ventilation 
WT-Tg21 149.6±18.8 376.8±30.1  
F=0.9 
p=0.3 
 
F=53.8 
p=0.0001 
 
F=0.002 
p=1.0 
Tg21 174.8±18.6 349.2±35.7 
Respiratory 
frequency         
WT-Tg21 227.2±25.8 318.8±12.1  
F=3.0 
p=0.1 
 
F=27.1 
p=0.0001 
 
F=0.4 
p=0.6 Tg21 208.8±7.9 282.0±13.6 
Tidal volume WT-Tg21 0.8±0.03 1.2±0.1  
F=0.0006 
p=1.0 
 
F=30.0 
p=0.0001 
 
F=0.3 
p=0.6 Tg21 0.7±0.1 1.2±0.08 
O2 
consumption 
WT-Tg21 4.4±0.1 
 
3.7±0.01  
F=0.6 
p=0.4 
 
F=9.9 
p=0.005 
 
F=0.03 
p=0.9 
Tg21 4.2±0.3 3.6±0.2 
CO2 
production 
WT-Tg21 2.8±0.1 2.4±0.07  
F=2.1 
p=0.2 
 
F=7.7 
p=0.01 
 
F=0.2 
p=0.6 Tg21 2.6±0.2 2.3±0.07 
VE/VO2 WT-Tg21 64.0±5.6 108.5±7.1  
F=2.1 
p=0.2 
 
F=16.9 
p=0.0008 
 
F=0.7 
p=0.4 Tg21 58.7±9.3 87.9±10.3 
VE/VCO2 WT-Tg21 64.0±5.6 168.9±11.4  
F=2.1 
p=0.2 
 
F=52.1 
p=0.0001 
 
F=1.0 
p=0.3 Tg21 58.7±9.3 137.5±16.3 
hematocrit WT-Tg21 46.5±1.1  
p=0.7 
Tg21 45.6.4±1.7 
plasma Epo WT-Tg21 33.7±4.9   
p=0.001 
Tg21 415.4±9.3 
brain Epo WT-Tg21 11.6±2.1  
p=0.001 
Tg21 182.6±8.4 
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